大麻素受体2型
立体化学
大麻素
药效团
同源建模
化学
铅化合物
对接(动物)
部分
大麻素受体
受体
生物化学
兴奋剂
酶
体外
医学
护理部
作者
Pradeep Paudel,Pankaj Pandey,Jason J. Paris,Nicole M. Ashpole,Fakhri Mahdi,Jun‐Mian Tian,Joseph Lee,Mei Wang,Min Xu,Amar G. Chittiboyina,Ikhlas A. Khan,Samir A. Ross,Xing-Cong Li
标识
DOI:10.1021/acs.jnatprod.3c00282
摘要
Bioassay-guided fractionation of the essential oil of Santalum album led to the identification of α-santalol (1) and β-santalol (2) as new chemotypes of cannabinoid receptor type II (CB2) ligands with Ki values of 10.49 and 8.19 μM, respectively. Nine structurally new α-santalol derivatives (4a–4h and 5) were synthesized to identify more selective and potent CB2 ligands. Compound 4e with a piperazine structural moiety demonstrated a Ki value of 0.99 μM against CB2 receptor and did not show binding activity against cannabinoid receptor type I (CB1) at 10 μM. Compounds 1, 2, and 4e increased intracellular calcium influx in SH-SY5Y human neuroblastoma cells that were attenuated by CB2 antagonism or inverse agonism, supporting the results that these compounds are CB2 agonists. Molecular docking showed that 1 and 4e had similar binding poses, exhibiting a unique interaction with Thr114 within the CB2 receptor, and that the piperazine structural moiety is required for the binding affinity of 4e. A 200 ns molecular dynamics simulation of CB2 complexed with 4e confirmed the stability of the complex. This structural insight lays a foundation to further design and synthesize more potent and selective α-santalol-based CB2 ligands for drug discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI